Business context and reporting period
Registrant: The filing is for Avra Medical Robotics, Inc. (AVRA), not SS Innovations International, Inc. It is an annual Form 10-K for the fiscal year ended December 31, 2020, signed September 6, 2022; it does not provide standalone fourth-quarter results.
AVRA was a development-stage medical robotics company developing an AI-guided autonomous robotic platform, initially for aesthetic skin-resurfacing procedures. The system had not generated revenue, and the company depended on external financing. The filing describes a later, non-binding August 2022 business-combination proposal involving SSI parties; that proposal was not part of 2020 operating results.
Financial results and condition
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $3,000 | $60,874 |
| Compensation expense | $812,190 | $2,509,792 |
| General and administrative expense | $287,737 | $752,018 |
| Total operating expenses | $1,102,927 | $3,366,232 |
| Net loss | $1,124,681 | $3,385,973 |
| Loss per share, basic and diluted | $0.05 | $0.16 |
| Net cash used in operating activities | $90,540 | $424,105 |
At year-end 2020, cash was $160,709, total assets were $317,870, current liabilities were $1,186,919, and stockholders’ deficit was $869,049. Current assets of $162,999 versus current liabilities imply a working-capital deficit of approximately $1.02 million. Current liabilities included $195,000 of related-party notes, $671,500 of accrued compensation, and $188,700 of accrued expenses. The filing does not report meaningful revenue or gross margins.
Cash increased from $28,474 at year-end 2019 to $160,709 at year-end 2020. Operating cash use was partly offset by $266,775 of financing cash flow, including private-placement proceeds and related-party borrowing. The company reported no off-balance-sheet arrangements and no income-tax provision.
Changes, outlook, risks and unusual items
- Year-over-year: Net loss narrowed by about 67%, chiefly as compensation expense and other operating expenses fell. Management attributed much of the expense reduction to the lower share price because substantial compensation and development costs were paid in stock. R&D expense also declined sharply. The filing does not show a corresponding increase in commercial activity; revenue remained zero.
- Going concern: The auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about AVRA’s ability to continue as a going concern, citing recurring losses, accumulated deficit and negative operating cash flows. Management said it expected to seek additional securities financing and possible development partnerships, but no funding source was committed. Failure to obtain financing could curtail operations; additional financing could materially dilute shareholders.
- Development and regulation: The robotic system was still under development. The company described FDA and international regulatory plans, preclinical and clinical work, and potential timelines, but these were expectations dependent on funding and regulatory feedback—not assured milestones. The robotic arm had a European CE mark; the filing does not establish that AVRA’s integrated system had FDA clearance or authorization to market.
- Business combination and interim financing, announced in 2022: AVRA disclosed a non-binding proposal under which SSI-party shareholders would own 95% of the combined company and existing AVRA shareholders 5%, subject to definitive agreements, due diligence and other conditions. AVRA reported advancing $900,000, documented by a one-year $1 million note bearing 7% interest and a 10% original issue discount. The note could convert into Cardio equity if unpaid at maturity. AVRA also described a $1 million investor note to fund the advance and the possibility of further financing; completion of the transaction was not assured.
- Other notable items: AVRA invested $210,000 in Avra Air, including $40,000 cash and $170,000 in AVRA shares, for a 49.8% interest and patent rights. A $25,331 investment loss was recorded in 2020. CEO-related loans and conversions, substantial stock-based compensation, and share/warrant issuance were also significant. The auditor’s report says it had served as auditor since 2021; the filing explains that periodic reporting had been interrupted after the prior auditor’s principal died and that AVRA’s shares had moved to the Expert Market.
- Controls and execution risks: Management disclosed material weaknesses involving missing written internal-control documentation and insufficient segregation of accounting duties, with remediation dependent on future resources. The filing states AVRA had four full-time and six part-time employees as of the report date. It also notes highly limited, sporadic trading and no assurance of a liquid market.
Important facts for investors to verify
- Confirm the registrant and security being analyzed: this is AVRA’s 2020 10-K, not a 2020 filing by SS Innovations International, Inc.
- Review the audited financial statements and notes for the going-concern warning, cash needs, accrued compensation, related-party debt, and non-cash equity compensation.
- Check current status and terms of the August 2022 proposed business combination, interim advances and convertible notes; the filing’s proposal was non-binding and subject to conditions.
- Verify the actual regulatory status of the integrated robotic system, required studies, funding available for development, and whether any stated commercialization timelines remain achievable.
- Assess the extent of potential dilution from outstanding options, warrants, equity plans and subsequent financing, and confirm whether disclosed internal-control weaknesses have been remediated.